Enanta Pharmaceuticals (ENTA) Competitors $6.30 +0.02 (+0.32%) (As of 02:02 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ENTA vs. PRTC, HUMA, ANAB, CRMD, MREO, XERS, ABVX, MGTX, RNAC, and GLUEShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include PureTech Health (PRTC), Humacyte (HUMA), AnaptysBio (ANAB), CorMedix (CRMD), Mereo BioPharma Group (MREO), Xeris Biopharma (XERS), ABIVAX Société Anonyme (ABVX), MeiraGTx (MGTX), Cartesian Therapeutics (RNAC), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. PureTech Health Humacyte AnaptysBio CorMedix Mereo BioPharma Group Xeris Biopharma ABIVAX Société Anonyme MeiraGTx Cartesian Therapeutics Monte Rosa Therapeutics PureTech Health (NASDAQ:PRTC) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations. Does the MarketBeat Community favor PRTC or ENTA? Enanta Pharmaceuticals received 308 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 56.91% of users gave Enanta Pharmaceuticals an outperform vote while only 45.00% of users gave PureTech Health an outperform vote. CompanyUnderperformOutperformPureTech HealthOutperform Votes945.00% Underperform Votes1155.00% Enanta PharmaceuticalsOutperform Votes31756.91% Underperform Votes24043.09% Do analysts rate PRTC or ENTA? PureTech Health presently has a consensus target price of $45.00, suggesting a potential upside of 124.89%. Enanta Pharmaceuticals has a consensus target price of $19.50, suggesting a potential upside of 208.06%. Given Enanta Pharmaceuticals' higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is PRTC or ENTA more profitable? PureTech Health has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -171.57%. PureTech Health's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PureTech HealthN/A N/A N/A Enanta Pharmaceuticals -171.57%-73.02%-28.70% Does the media favor PRTC or ENTA? In the previous week, PureTech Health had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 2 mentions for PureTech Health and 0 mentions for Enanta Pharmaceuticals. PureTech Health's average media sentiment score of 0.66 beat Enanta Pharmaceuticals' score of 0.00 indicating that PureTech Health is being referred to more favorably in the media. Company Overall Sentiment PureTech Health Positive Enanta Pharmaceuticals Neutral Which has higher valuation & earnings, PRTC or ENTA? PureTech Health has higher earnings, but lower revenue than Enanta Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPureTech Health$3.33M143.87-$65.70MN/AN/AEnanta Pharmaceuticals$67.64M1.98-$116.04M-$5.48-1.16 Which has more volatility & risk, PRTC or ENTA? PureTech Health has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Do institutionals & insiders hold more shares of PRTC or ENTA? 0.0% of PureTech Health shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryPureTech Health beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$134.16M$6.61B$5.16B$9.10BDividend YieldN/A2.99%5.12%4.26%P/E Ratio-1.1610.6387.5117.12Price / Sales1.98194.281,136.45119.65Price / CashN/A57.1643.2337.85Price / Book1.045.104.784.77Net Income-$116.04M$151.83M$120.55M$225.50M7 Day Performance0.32%-1.19%-1.64%-1.29%1 Month Performance-32.23%-4.73%14.04%0.45%1 Year Performance-30.82%8.89%28.88%15.38% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals3.8338 of 5 stars$6.30+0.3%$19.50+209.5%-31.4%$133.52M$67.64M-1.15145PRTCPureTech Health2.0016 of 5 stars$22.12+8.7%$45.00+103.4%-20.5%$529.60M$3.33M0.00100High Trading VolumeHUMAHumacyte3.366 of 5 stars$4.20+2.4%$13.00+209.5%+61.1%$528.61M$1.57M-3.06150Analyst ForecastGap UpANABAnaptysBio2.319 of 5 stars$17.01+9.1%$45.09+165.1%-29.8%$517.61M$17.16M-2.80100CRMDCorMedix1.8432 of 5 stars$8.39+0.1%$15.20+81.2%+128.5%$509.08M$12.26M-10.3530Positive NewsMREOMereo BioPharma Group2.0919 of 5 stars$3.27-12.6%$7.40+126.3%+57.3%$507.33M$1M0.0040Positive NewsGap DownHigh Trading VolumeXERSXeris Biopharma3.6063 of 5 stars$3.40+3.7%$4.87+43.1%+67.0%$506.87M$163.91M-7.29290Positive NewsABVXABIVAX Société Anonyme2.2307 of 5 stars$7.98+12.2%$38.67+384.5%-32.2%$505.52MN/A0.0061Positive NewsGap UpMGTXMeiraGTx3.879 of 5 stars$6.41+4.7%$23.50+266.6%-13.0%$500.96M$13.93M-5.06300RNACCartesian Therapeutics2.4696 of 5 stars$19.06+2.0%$43.00+125.6%-11.2%$484.51M$26M-0.3537GLUEMonte Rosa Therapeutics1.9251 of 5 stars$7.78+2.9%$16.00+105.7%+20.7%$477.98M$14.98M-4.1390 Related Companies and Tools Related Companies PRTC Competitors HUMA Competitors ANAB Competitors CRMD Competitors MREO Competitors XERS Competitors ABVX Competitors MGTX Competitors RNAC Competitors GLUE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
